Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J (2019) Nasopharyngeal carcinoma. Lancet 394:64–80

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249

Article  PubMed  Google Scholar 

Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D et al (2022) NCCN Guidelines(R) insights: head and neck cancers, version 1.2022. J Natl Compr Canc Netw 20:224–234

Article  PubMed  Google Scholar 

Bao Y, Peng F, Zhou QC, Yu ZH, Li JC, Cheng ZB et al (2015) Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer. Radiother Oncol 114:161–166

Article  CAS  PubMed  Google Scholar 

Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K et al (2005) Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 8:283–290

PubMed  Google Scholar 

Cui C, Mao L, Chi Z, Si L, Sheng X, Kong Y et al (2013) A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther 21:1456–1463

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li BL, Hu XL, Zhao XH, Sun HG, Zhou CY, Zhang Y (2015) Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: a clinical study. J Chemother 27:301–306

Article  CAS  PubMed  Google Scholar 

Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E et al (2023) Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 388:1657–1667

Article  CAS  PubMed  Google Scholar 

Lee CG, Heijn M, Di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C et al (2000) Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565–5570

CAS  PubMed  Google Scholar 

Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374–3378

CAS  PubMed  Google Scholar 

Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ et al (2008) Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 14:2210–2219

Article  CAS  PubMed  Google Scholar 

Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J et al (2012) Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 13:172–180

Article  CAS  PubMed  Google Scholar 

Lee N, Harris J, Pfister DG, Kim J, Garden AS, Mechalakos JG et al (2020) Long-term update of a phase II study of concurrent chemoradiotherapy using radiation + bevacizumab (BV) for locally or regionally advanced nasopharyngeal cancer (NPC): RTOG 0615. Int J Radiat Oncol Biol Phys 106:1119

Article  Google Scholar 

Li Y, Jin F, Wu W, Long J, Gong X, Chen G et al (2015) Clinical results of recombinant human endostatin combined with chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi 37:128–132

PubMed  Google Scholar 

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1

Article  PubMed  PubMed Central  Google Scholar 

Al-Sarraf M, Leblanc M, Giri PG, Fu KK, Cooper J, Vuong T et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16:1310–1317

Article  CAS  PubMed  Google Scholar 

Wu F, Wang R, Lu H, Wei B, Feng G, Li G et al (2014) Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study. Radiother Oncol 112:106–111

Article  PubMed  Google Scholar 

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

Article  CAS  PubMed  Google Scholar 

Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31

Article  CAS  PubMed  Google Scholar 

Jiang Q, Huang JH, Hu B, He YF (2013) Efficacy of recombinant human endostatin combined with chemotherapy in the treatment of advanced nasopharyngeal carcinoma. Chin J Otorhinolaryngol-Skull Base Surg 19:365–367

CAS  Google Scholar 

Cao SQ, Zhu CY, Zhang K (2017) Effects of recombinant human endostatin combined with chemoradiotherapy on clinical efficacy, prognosis and serum vascular endothelial growth factor for nasopharyngeal carcinoma. Chin J Gerontol 37:4290–4292

CAS  Google Scholar 

Jiang H, Si YF, Qin YD, Zhang Z, Huang B, Lu JL et al (2013) Clinical efficacy of Endostar combined with chemoradiotherapy in the treatment of nasopharyngeal carcinoma. Glob Tradit Chin Med 6:111–112

Google Scholar 

Zhang F, Yuan T, Gao M (2019) Efficacy of chemoradiotherapy combined with bevacizumab in patients with nasopharyngeal carcinoma: a comparative study. J BUON 24:1252–1258

PubMed  Google Scholar 

Yin Y, Zhou Z, Li Z, Shen M, Qin Y, Yang C et al (2022) Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study. Radiat Oncol 17:135

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhan D, Chen Z, Yang D, Wen J, Liu W (2022) Clinical effect of apatinib mesylate tablets combined with paclitaxel concurrent radiotherapy and chemotherapy in the first-line treatment of locally advanced nasopharyngeal carcinoma. Emerg Med Int 2022:6293816

Article  PubMed  PubMed Central  Google Scholar 

Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844

Article  CAS  PubMed  Google Scholar 

Yang X, Zhang Y, Hosaka K, Andersson P, Wang J, Tholander F et al (2015) VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients. Proc Natl Acad Sci U S A 112:E2900-2909

CAS  PubMed  PubMed Central  Google Scholar 

Irawan C, Nufus H, Rachmadi L, Harimurti K, Munandar A, Yunus RE (2022) The relationship of vascular endothelial growth factor and osteopontin expression with 3-year progression-free survival of locally advanced nasopharyngeal cancer patients treated with platinum-based chemoradiation. Contemp Oncol (Pozn) 26:220–228

CAS  PubMed  Google Scholar 

Mai HQ, Zeng ZY, Zhang CQ, Feng KT, Guo X, Mo HY et al (2006) Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma. Cancer 106:1548–1553

Article  CAS  PubMed  Google Scholar 

Doustjalali SR, Yusof R, Govindasamy GK, Bustam AZ, Pillay B, Hashim OH (2006) Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression. J Med Invest 53:20–28

Article  PubMed  Google Scholar 

Cho WC, Yip TT, Yip C, Yip V, Thulasiraman V, Ngan RK et al (2004) Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10:43–52

Article  CAS  PubMed  Google Scholar 

Gong X, Wang L, Wu W, Li Y, Long J, Chen X et al (2022) The treatment combining antiangiogenesis with chemoradiotherapy impinges on the peripheral circulation vascular endothelial cells and therapeutic effect in the patients with locally advanced nasopharyngeal carcinoma. Biomed Res Int 2022:1787854

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Tian Y, Jin F, Wu W, Long J, Ouyang J et al (2020) A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update. Curr Probl Cancer 44:100492

Article  PubMed  Google Scholar 

Zhang F (2021) Clinical observation of recombinant human vascular endostatin combined with chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. Jishou University

Google Scholar 

Ding WB, Zhang PX, Shi L, Deng L, Zhang J, Yuan KH et al (2014) Efficacy of recombinant human endostatin combined with cisplatin plus 5-FU chemotherapy concurrent with radiotherapy for advanced nasopharyngeal carcinoma. Chin J Clin Oncol Rehabil 21:1465–1467

Google Scholar